File Download
  • No File Attached
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Identification of a novel CD4i human monoclonal antibody Fab that neutralizes HIV-1 primary isolates from different clades
  • Basic View
  • Metadata View
  • XML View
TitleIdentification of a novel CD4i human monoclonal antibody Fab that neutralizes HIV-1 primary isolates from different clades
 
AuthorsZhang, MY2 1
Shu, Y2
Sidorov, I2
Dimitrov, DS2
 
Issue Date2004
 
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/antiviral
 
CitationAntiviral Research, 2004, v. 61 n. 3, p. 161-164 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.antiviral.2003.09.009
 
AbstractA new human monoclonal antibody (hmAb), designated m16, was selected by sequential antigen panning (SAP) of a human phage display library against recombinant soluble HIV-1 envelope glycoproteins (Envs) (gp140s) and their complexes with soluble CD4. It bound with high (nM) affinity to gp120 and gp140; the binding was further enhanced by interactions of the Envs with CD4. m16 inhibited cell fusion mediated by the Envs of 9 HIV-1 isolates from clades A, B, E and G with potency on average comparable to that of the broadly neutralizing human monoclonal antibody Fab X5. The identification of a new hmAb with broad neutralizing activity that exhibits differential inhibitory profile suggests a potential for its use as a component of anti-HIV-1 treatments.
 
ISSN0166-3542
2012 Impact Factor: 3.925
2012 SCImago Journal Rankings: 1.169
 
DOIhttp://dx.doi.org/10.1016/j.antiviral.2003.09.009
 
ISI Accession Number IDWOS:000189131000003
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorZhang, MY
 
dc.contributor.authorShu, Y
 
dc.contributor.authorSidorov, I
 
dc.contributor.authorDimitrov, DS
 
dc.date.accessioned2012-08-08T08:49:29Z
 
dc.date.available2012-08-08T08:49:29Z
 
dc.date.issued2004
 
dc.description.abstractA new human monoclonal antibody (hmAb), designated m16, was selected by sequential antigen panning (SAP) of a human phage display library against recombinant soluble HIV-1 envelope glycoproteins (Envs) (gp140s) and their complexes with soluble CD4. It bound with high (nM) affinity to gp120 and gp140; the binding was further enhanced by interactions of the Envs with CD4. m16 inhibited cell fusion mediated by the Envs of 9 HIV-1 isolates from clades A, B, E and G with potency on average comparable to that of the broadly neutralizing human monoclonal antibody Fab X5. The identification of a new hmAb with broad neutralizing activity that exhibits differential inhibitory profile suggests a potential for its use as a component of anti-HIV-1 treatments.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationAntiviral Research, 2004, v. 61 n. 3, p. 161-164 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.antiviral.2003.09.009
 
dc.identifier.doihttp://dx.doi.org/10.1016/j.antiviral.2003.09.009
 
dc.identifier.epage164
 
dc.identifier.isiWOS:000189131000003
 
dc.identifier.issn0166-3542
2012 Impact Factor: 3.925
2012 SCImago Journal Rankings: 1.169
 
dc.identifier.issue3
 
dc.identifier.pmid15168796
 
dc.identifier.scopuseid_2-s2.0-0842311270
 
dc.identifier.spage161
 
dc.identifier.urihttp://hdl.handle.net/10722/157381
 
dc.identifier.volume61
 
dc.languageeng
 
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/antiviral
 
dc.publisher.placeNetherlands
 
dc.relation.ispartofAntiviral Research
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAntibodies, Monoclonal - Immunology
 
dc.subject.meshAntibody Affinity
 
dc.subject.meshAntigens, Cd4 - Immunology
 
dc.subject.meshCell Fusion
 
dc.subject.meshGene Products, Env - Immunology
 
dc.subject.meshGenotype
 
dc.subject.meshHiv Antibodies - Immunology
 
dc.subject.meshHiv Antigens - Immunology
 
dc.subject.meshHiv Envelope Protein Gp120 - Immunology
 
dc.subject.meshHiv-1 - Genetics - Immunology
 
dc.subject.meshHumans
 
dc.subject.meshImmunoglobulin Fab Fragments - Immunology
 
dc.subject.meshNeutralization Tests
 
dc.subject.meshPeptide Library
 
dc.subject.meshProtein Binding
 
dc.subject.meshRecombinant Proteins - Immunology
 
dc.subject.meshEnv Gene Products, Human Immunodeficiency Virus
 
dc.titleIdentification of a novel CD4i human monoclonal antibody Fab that neutralizes HIV-1 primary isolates from different clades
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Zhang, MY</contributor.author>
<contributor.author>Shu, Y</contributor.author>
<contributor.author>Sidorov, I</contributor.author>
<contributor.author>Dimitrov, DS</contributor.author>
<date.accessioned>2012-08-08T08:49:29Z</date.accessioned>
<date.available>2012-08-08T08:49:29Z</date.available>
<date.issued>2004</date.issued>
<identifier.citation>Antiviral Research, 2004, v. 61 n. 3, p. 161-164</identifier.citation>
<identifier.issn>0166-3542</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/157381</identifier.uri>
<description.abstract>A new human monoclonal antibody (hmAb), designated m16, was selected by sequential antigen panning (SAP) of a human phage display library against recombinant soluble HIV-1 envelope glycoproteins (Envs) (gp140s) and their complexes with soluble CD4. It bound with high (nM) affinity to gp120 and gp140; the binding was further enhanced by interactions of the Envs with CD4. m16 inhibited cell fusion mediated by the Envs of 9 HIV-1 isolates from clades A, B, E and G with potency on average comparable to that of the broadly neutralizing human monoclonal antibody Fab X5. The identification of a new hmAb with broad neutralizing activity that exhibits differential inhibitory profile suggests a potential for its use as a component of anti-HIV-1 treatments.</description.abstract>
<language>eng</language>
<publisher>Elsevier BV. The Journal&apos;s web site is located at http://www.elsevier.com/locate/antiviral</publisher>
<relation.ispartof>Antiviral Research</relation.ispartof>
<subject.mesh>Antibodies, Monoclonal - Immunology</subject.mesh>
<subject.mesh>Antibody Affinity</subject.mesh>
<subject.mesh>Antigens, Cd4 - Immunology</subject.mesh>
<subject.mesh>Cell Fusion</subject.mesh>
<subject.mesh>Gene Products, Env - Immunology</subject.mesh>
<subject.mesh>Genotype</subject.mesh>
<subject.mesh>Hiv Antibodies - Immunology</subject.mesh>
<subject.mesh>Hiv Antigens - Immunology</subject.mesh>
<subject.mesh>Hiv Envelope Protein Gp120 - Immunology</subject.mesh>
<subject.mesh>Hiv-1 - Genetics - Immunology</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Immunoglobulin Fab Fragments - Immunology</subject.mesh>
<subject.mesh>Neutralization Tests</subject.mesh>
<subject.mesh>Peptide Library</subject.mesh>
<subject.mesh>Protein Binding</subject.mesh>
<subject.mesh>Recombinant Proteins - Immunology</subject.mesh>
<subject.mesh>Env Gene Products, Human Immunodeficiency Virus</subject.mesh>
<title>Identification of a novel CD4i human monoclonal antibody Fab that neutralizes HIV-1 primary isolates from different clades</title>
<type>Article</type>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/j.antiviral.2003.09.009</identifier.doi>
<identifier.pmid>15168796</identifier.pmid>
<identifier.scopus>eid_2-s2.0-0842311270</identifier.scopus>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-0842311270&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>61</identifier.volume>
<identifier.issue>3</identifier.issue>
<identifier.spage>161</identifier.spage>
<identifier.epage>164</identifier.epage>
<identifier.isi>WOS:000189131000003</identifier.isi>
<publisher.place>Netherlands</publisher.place>
</item>
Author Affiliations
  1. SAIC-Frederick
  2. National Institutes of Health, Bethesda